Novartis expects profit and sales to grow further this year after beating analysts’ expectations, boosted by revenue from its key drugs.

Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit percentage this year, helped by lower costs and growth from drugs such as eye treatment Vabysmo and cancer drug Phesgo.

The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the CEO said it remained committed to keeping its R&D spending broadly flat in 2025.